Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood’s Ark Invest added to Tesla, SoFi, and Recursion Pharmaceuticals, with Tesla down ~7.5% on the day despite Q2 deliveries rising 25% YoY to 480,126 vehicles (vs 406,024 expected). SoFi is ~30% off its 2026 decline and traded at ~31x forward earnings after Ark added daily, while Recursion (market cap ~$2B) is priced below $4 with Ark owning ~$115M (~5% of shares). The news is largely positioning/activity-driven rather than a fundamental earnings catalyst, but it could still influence sentiment in high-growth fintech/AI names.

Analysis

TSLA is the cleaner near-term short even after the delivery surprise. When volume is helped by promotional pull-forward and exogenous fuel costs, the market usually looks through the unit print and focuses on gross margin mix, so the first move can be wrong but the 1-4 week setup into earnings is more fragile than the headline suggests. The second-order effect is price pressure across European EVs and suppliers if Tesla keeps using incentives to defend share, but the real falsifier is a Q2 margin print that shows incentives were temporary rather than structural.

SOFI is a better quality story, but it is still priced like a duration asset. Repeated buying may cushion the float, yet at roughly low-30s forward earnings the stock needs continued credit cleanliness and funding-cost control; if either slips, the multiple can compress fast because there is little valuation slack. Relative value favors SOFI only if the next 1-2 quarters confirm operating leverage, not just member growth.

RXRX is mostly an optionality-and-dilution trade over 6-18 months. ARK ownership can support liquidity, but it also makes the stock more dependent on capital-market sentiment than on near-term fundamentals; without a partnership or clinical catalyst, burn rate remains the dominant variable. The contrarian view is that AI drug discovery still needs clinical proof, so the market may be overpaying for a platform story before it has earned revenue durability.

Key Decisions for Investors

• Short TSLA into any post-delivery bounce via a 1-2 month put spread ahead of July 22 earnings; risk/reward is attractive if margins show promo-led compression. Falsify if automotive gross margin ex-credits holds up and management raises 2H guidance.
• Build SOFI only on weakness or as a relative-value long SOFI / short XLF basket over the next 1-3 months; thesis is multiple support from sustained growth and operating leverage. Cut if credit losses or funding costs re-accelerate faster than revenue.
• Do not own RXRX common ahead of a financing or partnership catalyst; if exposure is required, use a small defined-risk call spread, not stock, because dilution risk dominates over the next 6-18 months.
• Treat TSLA and RXRX as event-driven names, not stable compounders; if both rally on flow, fade into strength rather than chase, because the market is likely overweighting sentiment and underweighting margin/cash-burn risk.